Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

The average life expectancy of people diagnosed with dementia ranges from nine years at age 60 to 4.5 years at age 85 for ...

Declining blood levels of two molecules that occur naturally in the body track closely with worsening Alzheimer's disease, particularly in women. Levels were found to drop gradually, from women with ...

Higher green tea consumption significantly reduces cerebral white matter lesions in older adults, offering potential ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...

According to Alzheimer's Society, around 982,000 people are living with dementia in the UK - this is expected to increase to ...